Anzeige
Mehr »
Montag, 20.10.2025 - Börsentäglich über 12.000 News
Homeland Uranium: Vom Geheimtipp zum potenziellen Entwicklerstar
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Business Wire

ZeitAktuelle NachrichtenRatingLeser
SoCorcept Therapeutics Incorporated: Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment613New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no...
► Artikel lesen
SoESMO 2025: Faeth Therapeutics' Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy389Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination extended mean progression-free...
► Artikel lesen
SoVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma415GFH375 resulted in a 41% ORR for patients with heavily pre-treated pancreatic ductal adenocarcinoma (68% had received 2 or more prior lines of therapy) at the 600 mg daily dose At month four...
► Artikel lesen
SoTubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025560TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September...
► Artikel lesen
SoGilead Sciences, Inc.: Trodelvy Reduces Risk of Disease Progression or Death by 38% Versus Chemotherapy as First-Line Therapy in Patients With Metastatic Triple-Negative Breast Cancer in ASCENT-03 Study562- Late-Breaking ASCENT-03 Data Simultaneously Presented at ESMO 2025 and Published in The New England Journal of Medicine - - With Two Positive Phase 3 Trials, Trodelvy Has Potential as the First...
► Artikel lesen
SaDaiichi Sankyo: ENHERTU Reduced the Risk of Disease Recurrence or Death by 53% Versus T-DM1 in Patients with High-Risk HER2 Positive Early Breast Cancer Following Neoadjuvant Therapy in DESTINY-Breast05 Phase 3 Trial718More than 92% of patients treated with Daiichi Sankyo and AstraZeneca's ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I...
► Artikel lesen
SaMerck & Co., Inc.: KEYTRUDA (pembrolizumab) Plus Padcev (enfortumab vedotin-ejfv) Reduced Risk of Event-Free Survival Events by 60% and Risk of Death by 50% for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery503First and only systemic regimen to demonstrate durable survival benefit in this patient population KEYNOTE-905 marks the fifth study of a KEYTRUDA-based regimen in an earlier stage of cancer...
► Artikel lesen
SaAstraZeneca: ENHERTU (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial488Highest reported pathologic complete response rate seen in a Phase III registrational trial for HER2-positive early breast cancer with favorable safety profile vs. standard treatment DESTINY-Breast11...
► Artikel lesen
SaMerck & Co., Inc.: KEYTRUDA (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer586Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology...
► Artikel lesen
SaBentley Systems, Incorporated: Bentley Systems gibt die Gewinner der Going Digital Awards 2025 bekannt416Das Unternehmen würdigt zudem wichtige Projekte mit den Founders' Honors, dem Bentley-Envision Award für nachhaltige Infrastruktur und dem Bentley Educator of the Year 2025. (Bentley Systems...
► Artikel lesen
SaDeciphera Pharmaceuticals Inc.: Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 2025387- Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and...
► Artikel lesen
SaGenmab Announces New Data Demonstrating Investigational Rinatabart Sesutecan (Rina-S) Achieved Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer491Updated data from the Phase 1/2 RAINFOL-01 trial showed rinatabart sesutecan (Rina-S) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR)...
► Artikel lesen
SaSalubris Biotherapeutics, Inc.: Salubris Biotherapeutics Announces Dose Escalation Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology 2025 Congress3725 confirmed partial responses (PRs) among 13 evaluable non-small cell lung cancer (NSCLC) patients (ORR 38%); 1 confirmed PR among 7 breast cancer patients Favorable safety and PK profile, with...
► Artikel lesen
SaKinaxis Inc.: Kinaxis beschleunigt mit der Einführung von Maestro Agents das Zeitalter der agentenbasierten Lieferkettenorchestrierung374KI-Agenten, die gemeinsam mit Ihnen planen und nicht nur für Sie, ermöglichen eine Kundenerfahrung der nächsten Generation der adaptiven Lieferkette Kinaxis® Inc. (TSX: KXS), ein weltweit führender...
► Artikel lesen
SaGenentech's Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer411- Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with standard-of-care...
► Artikel lesen
SaKolibri Global Energy Inc. Provides Update Regarding Information Circular Disclosure323Kolibri Global Energy Inc. (the "Company" or "Kolibri") (TSX: KEI, NASDAQ: KGEI)wishes to provide an update to certain information contained in the management information circular and related materials...
► Artikel lesen
SaQualcomm Incorporated: Qualcomm kündigt Quartalsdividenden-Ausschüttung an328Qualcomm Incorporated (NASDAQ: QCOM) gab heute eine Quartalsdividende in bar in Höhe von 0,89 US-Dollar je Stammaktie bekannt, zahlbar am 18. Dezember 2025 an die Aktionäre, die zum Geschäftsschluss...
► Artikel lesen
SaSTEP Energy Services Ltd. Agrees to $5.50 Per Share Take Private Transaction With Funds Advised by ARC Financial Corp.101CALGARY, Alberta--(BUSINESS WIRE)--Further to its news release of September 25, 2025 announcing receipt of a non-binding offer from ARC Financial Corp., STEP Energy Services Ltd. ("STEP" or the "Company")...
► Artikel lesen
FrIllumynt berichtet über Geschäftsentwicklung im dritten Quartal 2025235Das dritte Quartal 2025 war wieder ein ereignisreiches Quartal für uns bei Illumynt. Neben der Ernennung eines neuen Geschäftsführers haben wir einige Initiativen umgesetzt, die unsere Organisation...
► Artikel lesen
FrEaton to announce third quarter 2025 earnings on November 4, 2025262Intelligent power management company Eaton (NYSE:ETN) will announce third quarter 2025 earnings on Tuesday, November 4, 2025, before the opening of the New York Stock Exchange. The company will host...
► Artikel lesen
FrGeneral Atomics Joins International Effort to Tackle One of Fusion's Biggest Hurdles and Unlock the Secrets of Fusion's Hottest Particles291Collaboration aims to boost efficiency and advance fusion power plant performance Researchers at General Atomics (GA) are lending their expertise to address one of fusion energy's greatest challenges:...
► Artikel lesen
FrProAmpac übernimmt den Geschäftsbereich Beutelverarbeitung von International Paper855ProAmpac, ein weltweit führendes Unternehmen im Bereich flexible Verpackungen und Materialwissenschaften, hat den Geschäftsbereich Beutelverarbeitung von International Paper ("IP"), einem weltweit...
► Artikel lesen
FrnVent Electric plc to Report Third Quarter 2025 Financial Results on October 31244nVent Electric plc (NYSE: NVT) ("nVent"), a global leader in electrical connection and protection solutions, will report third quarter 2025 financial results on Friday, October 31, 2025. The financial...
► Artikel lesen
FrInformation Services Group, Inc.: Europa führt KI-gestützte Workday-Optimierung ein269Unternehmen integrieren KI-, Automatisierungs- und ESG-Tools, um ihre betriebliche Effizienz und Compliance zu verbessern, so der Bericht ISG Provider Lens Europäische Unternehmen, die auf die...
► Artikel lesen
FrAvanzanite Bioscience B.V.: Avanzanite-Bioscience-Partner Agios gibt positive CHMP-Stellungnahme für PYRUKYND (Mitapivat) bei erwachsenen Patienten mit Thalassämie bekannt201Avanzanite ging im Juni 2025 eine exklusive Partnerschaft mit Agios zur Steuerung der Kommerzialisierung von PYRUKYND in Europa ein Die Europäische Kommission wird die CHMP-Stellungnahme...
► Artikel lesen